Multivariable linear regression analysis of the rate of renal function decline (eGFR slope)
| Characteristics . | All patients (n = 1130) . | Patients never treated with corticosteroid/immunosuppressors during the follow-up (n = 582) . |
|---|---|---|
| M1 | −0.03 (P=0.28) | −0.06 (P=0.18) |
| E1 | −0.06 (P=0.07) | 0.08 (P=0.07) |
| S1 | −0.05 (P=0.14) | −0.07 (P=0.14) |
| T1–2 | −0.16 (P<0.001*) | −0.14 (P=0.003*) |
| Crescents (C1–2) | 0.002 (P=0.95) | −0.11 (P=0.01*) |
| Arteriosclerosis | −0.002 (P=0.94) | 0.03 (P=0.51) |
| Gender (male) | 0.02 (P=0.42) | −0.006 (P=0.89) |
| Age | −0.01 (P=0.76) | 0.004 (P=0.94) |
| Baseline eGFR | −0.18 (P<0.001*) | −0.11 (P=0.05*) |
| Baseline MAP | −0.12 (P<0.001*) | −0.08 (P=0.10) |
| Baseline proteinuria | −0.08 (P=0.02*) | −0.13 (P=0.004*) |
| Baseline BMI | 0.001 (P=0.97) | −0.02 (P=0.74) |
| Characteristics . | All patients (n = 1130) . | Patients never treated with corticosteroid/immunosuppressors during the follow-up (n = 582) . |
|---|---|---|
| M1 | −0.03 (P=0.28) | −0.06 (P=0.18) |
| E1 | −0.06 (P=0.07) | 0.08 (P=0.07) |
| S1 | −0.05 (P=0.14) | −0.07 (P=0.14) |
| T1–2 | −0.16 (P<0.001*) | −0.14 (P=0.003*) |
| Crescents (C1–2) | 0.002 (P=0.95) | −0.11 (P=0.01*) |
| Arteriosclerosis | −0.002 (P=0.94) | 0.03 (P=0.51) |
| Gender (male) | 0.02 (P=0.42) | −0.006 (P=0.89) |
| Age | −0.01 (P=0.76) | 0.004 (P=0.94) |
| Baseline eGFR | −0.18 (P<0.001*) | −0.11 (P=0.05*) |
| Baseline MAP | −0.12 (P<0.001*) | −0.08 (P=0.10) |
| Baseline proteinuria | −0.08 (P=0.02*) | −0.13 (P=0.004*) |
| Baseline BMI | 0.001 (P=0.97) | −0.02 (P=0.74) |
Dependent variable: rate of renal function decline. Data are presented as standardized regression coefficient (beta) and P-value. *Statistically significant P-values. Pathology findings are defined according to the Oxford classification [6]: M, E, S, T, crescents and arteriosclerosis adjusted for age, gender and baseline data of eGFR, MAP and proteinuria. The analysis is country weighted.
Multivariable linear regression analysis of the rate of renal function decline (eGFR slope)
| Characteristics . | All patients (n = 1130) . | Patients never treated with corticosteroid/immunosuppressors during the follow-up (n = 582) . |
|---|---|---|
| M1 | −0.03 (P=0.28) | −0.06 (P=0.18) |
| E1 | −0.06 (P=0.07) | 0.08 (P=0.07) |
| S1 | −0.05 (P=0.14) | −0.07 (P=0.14) |
| T1–2 | −0.16 (P<0.001*) | −0.14 (P=0.003*) |
| Crescents (C1–2) | 0.002 (P=0.95) | −0.11 (P=0.01*) |
| Arteriosclerosis | −0.002 (P=0.94) | 0.03 (P=0.51) |
| Gender (male) | 0.02 (P=0.42) | −0.006 (P=0.89) |
| Age | −0.01 (P=0.76) | 0.004 (P=0.94) |
| Baseline eGFR | −0.18 (P<0.001*) | −0.11 (P=0.05*) |
| Baseline MAP | −0.12 (P<0.001*) | −0.08 (P=0.10) |
| Baseline proteinuria | −0.08 (P=0.02*) | −0.13 (P=0.004*) |
| Baseline BMI | 0.001 (P=0.97) | −0.02 (P=0.74) |
| Characteristics . | All patients (n = 1130) . | Patients never treated with corticosteroid/immunosuppressors during the follow-up (n = 582) . |
|---|---|---|
| M1 | −0.03 (P=0.28) | −0.06 (P=0.18) |
| E1 | −0.06 (P=0.07) | 0.08 (P=0.07) |
| S1 | −0.05 (P=0.14) | −0.07 (P=0.14) |
| T1–2 | −0.16 (P<0.001*) | −0.14 (P=0.003*) |
| Crescents (C1–2) | 0.002 (P=0.95) | −0.11 (P=0.01*) |
| Arteriosclerosis | −0.002 (P=0.94) | 0.03 (P=0.51) |
| Gender (male) | 0.02 (P=0.42) | −0.006 (P=0.89) |
| Age | −0.01 (P=0.76) | 0.004 (P=0.94) |
| Baseline eGFR | −0.18 (P<0.001*) | −0.11 (P=0.05*) |
| Baseline MAP | −0.12 (P<0.001*) | −0.08 (P=0.10) |
| Baseline proteinuria | −0.08 (P=0.02*) | −0.13 (P=0.004*) |
| Baseline BMI | 0.001 (P=0.97) | −0.02 (P=0.74) |
Dependent variable: rate of renal function decline. Data are presented as standardized regression coefficient (beta) and P-value. *Statistically significant P-values. Pathology findings are defined according to the Oxford classification [6]: M, E, S, T, crescents and arteriosclerosis adjusted for age, gender and baseline data of eGFR, MAP and proteinuria. The analysis is country weighted.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
